Catalog No. | HB011066 |
---|---|
Species reactivity | Human |
Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
Host species | Humanized |
Isotype | IgG1-kappa |
Expression system | Mammalian Cells |
Clonality | Monoclonal |
Target | Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22 |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Protein A/G purified from cell culture supernatant. |
Accession | P20273 |
Form | Liquid |
Storage buffer | 0.01M PBS, pH 7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names | ACD22-VCMMAE, DCDT2980S, FCU2803, RG-7593, RO5541072-000 |
Background | HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). • Targeting Human CD22/Siglec-2 with Dimeric Sialosides as Novel Oligosaccharide Mimetics., PMID:35881556 • Siglec-1 and -2 as potential biomarkers in autoimmune disease., PMID:26752092 • Siglecs in Brain Function and Neurological Disorders., PMID:31546700 • Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes., PMID:9636173 • Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus., PMID:30355653 • Versatile biosynthetic engineering of sialic acid in living cells using synthetic sialic acid analogues., PMID:11751912 • Characterisation of the Dynamic Interactions between Complex N-Glycans and Human CD22., PMID:31095840 • Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs., PMID:10722703 • Insights into the transcriptional regulation of CD22 in B cell chronic lymphocytic leukemia., PMID:40054694 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Pinatuzumab.
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France